15407-81-5Relevant academic research and scientific papers
Heterocyclization of isoniazid: Synthesis and antimicrobial activity of some new pyrimidine, 1, 3-thiazole, 1, 2, 4-thiadiazole, and 1, 2, 4-triazole derivatives derived from isoniazid
Farhan, Mona E.,Assy, Mohammed G.
, p. 171 - 180 (2019/02/12)
THE (2) affordedREACTION cinnamoylof isonicotinic thiosemicarbazidehydrazide derivative\(1)(isoniazid) 3. Treatmentwith cinnamoyl of 3 withisothiocyanate lead acetate
Synthesis of pyridine-containing α-hydrazino phosphonates by two-component catalytic procedure
Matveeva,Podrugina,Kolesnikova,Zefirov
experimental part, p. 254 - 257 (2011/11/05)
Pyridine-containing α-hydrazino phosphonates were synthesized in high yields by reaction of hydrazones of pyridine series with diethyl phosphite in the presence of [tetra(tert-butyl)-phthalocyanine]aluminum chloride as a catalyst.
Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid
Hearn, Michael J.,Cynamon, Michael H.,Chen, Michaeline F.,Coppins, Rebecca,Davis, Jessica,Joo-On Kang, Helen,Noble, Abigail,Tu-Sekine, Becky,Terrot, Marianne S.,Trombino, Daniella,Thai, Minh,Webster, Eleanor R.,Wilson, Rebecca
experimental part, p. 4169 - 4178 (2009/12/04)
Structural modification of the frontline antitubercular isonicotinic acid hydrazide (INH) provides lipophilic adaptations (3-46) of the drug in which the hydrazine moiety of the parent compound has been chemically blocked from the deactivating process of N2-acetylation by N-arylaminoacetyl transferases. As a class, these compounds show high levels of activity against Mycobacterium tuberculosis in vitro and in tuberculosis-infected macrophages. They provide strong protection in tuberculosis-infected mice and have low toxicity. With some representatives of this class achieving early peak plasma concentrations approximately three orders of magnitude above minimum inhibitory concentration, they may serve as tools for improving our understanding of INH-based treatment modalities, particularly for those patients chronically underdosed in conventional INH therapy.
